公开(公告)号：US4325441A

公开(公告)日：1982-04-20

申请号：US147271

申请日：1980-05-06

申请人： Hiroshi Nakatani ,  Masahide Ishida ,  Hachizou Yamamoto

发明人： Hiroshi Nakatani ,  Masahide Ishida ,  Hachizou Yamamoto

IPC分类号： G06F3/16 ,  G01G23/01 ,  G01G23/38 ,  G01G23/46 ,  G07G1/01 ,  G07G1/12 ,  G01G23/22 ,  G01G23/00 ,  G01G23/18

CPC分类号： G06Q30/04 ,  G01G23/01 ,  G01G23/38 ,  G01G23/46 ,  G07G1/12

摘要： An electronic cash register electrically communicates with an electronic weighing scale. An interface circuit is included in the electronic cash register for introducing weight information data from the electronic weighing scale into the electronic cash register. An abnormal condition detection system is included in the electronic cash register for detecting an abnormal condition occurring within the electronic weighing scale. The electronic cash register includes a synthetic speech sound generation system for audibly informing an operator of the abnormal condition detected by the abnormal condition detection system.

摘要翻译： 电子收款机与电子称重秤电连通。 接收电路包括在电子收款机中，用于将来自电子秤的重量信息数据引入电子收款机。 电子收款机中包括异常状况检测系统，用于检测电子秤内发生的异常情况。 电子收款机包括用于向操作者可听地通知由异常状态检测系统检测到的异常状况的合成语音产生系统。

公开(公告)号：US3995059A

公开(公告)日：1976-11-30

申请号：US174149

申请日：1971-08-23

申请人： Toshitsugu Fukumaru ,  Noritaka Hamma ,  Hiroshi Nakatani ,  Hideaki Fukushima ,  Katsuyuki Toki

发明人： Toshitsugu Fukumaru ,  Noritaka Hamma ,  Hiroshi Nakatani ,  Hideaki Fukushima ,  Katsuyuki Toki

IPC分类号： C07C233/00 ,  C07C233/02 ,  C07D295/185 ,  A01N9/20 ,  A01N9/24

CPC分类号： C07D295/185 ,  C07C233/00 ,  C07C233/02

摘要： A pharmaceutical composition consisting essentially of pharmaceutically effective amount of an N-substituted fatty acid amide of the formula, ##EQU1## wherein R is a C.sub.13 - C.sub.25 aliphatic hydrocarbon chain or a C.sub.13 - C.sub.25 hydroxylated aliphatic hydrocarbon chain and RCO-- is other than isostearoyl; R' is d- or l-.alpha.-C.sub.1 - C.sub.4 alkylbenzyl, racemic-, d- or l-.alpha.-C.sub.1 - C.sub.4 alkylbenzyl substituted in the benzene ring with one or two substituents selected from the group consisting of C.sub.1 - C.sub.4 alkyl, C.sub.1 - C.sub.4 alkoxy, halogen and nitro, or racemic-, d- or l-.alpha.-benzylbenzyl; R" is hydrogen; or R' and R" together are cyclohexyl; and when RCO-- is isotearoyl R' is alkyl, alkenyl, cycloalkyl, alkylcycloalkyl, hydroxycycloalkyl, alkoxycycloalkyl, alkylphenyl, hydroxyphenyl, alkoxyphenyl, halogenophenyl, halogen-alkyl-substituted phenyl, halogenoalkyl- and halogen-substituted phenyl, alkoxy- and halogen-substituted phenyl, benzyl, racemic-, d- or l-.alpha.-C.sub.1 - C.sub.4 alkylbenzyl, benzyl substituted in the benzene ring with lower alkyl or lower alkoxy, racemic-, d- or l-.alpha.-benzylbenzyl or hydroxybenzyl, and R" is hydrogen or any one of the groups represented by R', and a pharmaceutically acceptable carrier, which is useful for lowering elevated levels of cholesterol in the blood.

摘要翻译： 基本上由药学有效量的式R'R-CO-N ANGLE R“的N-取代脂肪酸酰胺组成的药物组合物，其中R是C 13 -C 25脂族烃链或C 13 -C 25羟基化脂族烃 链和RCO-不是异硬脂酰基; R'是在苯环中被一个或两个选自C 1 -C 4烷基，C 1 -C 4烷基，C 1 -C 4烷基，C 1 -C 4烷基， C 1 -C 4烷氧基，卤素和硝基，或外消旋 - ，d-或1-α-苄基苄基; R“是氢; 或R'和R“一起为环己基; 当RCO-为异月桂酰基R'为烷基，烯基，环烷基，烷基环烷基，羟基环烷基，烷氧基环烷基，烷基苯基，羟基苯基，烷氧基苯基，卤代苯基，卤代 - 烷基取代的苯基，卤代烷基 - 和卤素取代的苯基，烷氧基 - 和卤素取代 苯基，苄基，外消旋 - ，d-或1-α-C 1 -C 4烷基苄基，在苯环中被低级烷基或低级烷氧基取代的苄基，外消旋 - ，d-或1-α-苄基苄基或羟基苄基，R“ 是氢或由R'表示的基团中的任何一个，以及可用于降低血液中胆固醇升高的药学上可接受的载体。